Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Shorr, Andrew F., Thomas P. Lodise, G Ralph Corey, Carisa De Anda, Edward Fang, Anita F. Das, and Philippe Prokocimer. “Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections..” Antimicrob Agents Chemother 59, no. 2 (February 2015): 864–71. https://doi.org/10.1128/AAC.03688-14.

PMID
25421472
Full Text

Corey, G Ralph, Samantha Good, Hai Jiang, Greg Moeck, Matthew Wikler, Sinikka Green, Paul Manos, et al. “Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study..” Clin Infect Dis 60, no. 2 (January 15, 2015): 254–62. https://doi.org/10.1093/cid/ciu778.

PMID
25294250
Full Text

Durkin, Michael J., and G Ralph Corey. “New developments in the management of severe skin and deep skin structure infections - focus on tedizolid..” Ther Clin Risk Manag 11 (2015): 857–62. https://doi.org/10.2147/TCRM.S64553.

PMID
26045667
Full Text

Corey, Ralph, Odin J. Naderer, William D. O’Riordan, Etienne Dumont, Lori S. Jones, Milena Kurtinecz, and John Z. Zhu. “Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections..” Antimicrob Agents Chemother 58, no. 11 (November 2014): 6518–27. https://doi.org/10.1128/AAC.03360-14.

PMID
25136015
Full Text

Moran, Gregory J., Edward Fang, G Ralph Corey, Anita F. Das, Carisa De Anda, and Philippe Prokocimer. “Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial..” Lancet Infect Dis 14, no. 8 (August 2014): 696–705. https://doi.org/10.1016/S1473-3099(14)70737-6.

PMID
24909499
Full Text

Corey, G Ralph, Heidi Kabler, Purvi Mehra, Sandeep Gupta, J Scott Overcash, Ashwin Porwal, Philip Giordano, et al. “Single-dose oritavancin in the treatment of acute bacterial skin infections..” N Engl J Med 370, no. 23 (June 5, 2014): 2180–90. https://doi.org/10.1056/NEJMoa1310422.

PMID
24897083
Full Text

Corey, G. R., M. H. Kollef, A. F. Shorr, E. Rubinstein, M. E. Stryjewski, A. Hopkins, and S. L. Barriere. “Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival..” Antimicrob Agents Chemother 58, no. 6 (June 2014). https://doi.org/10.1128/AAC.02899-14.

PMID
24829393
Full Text

Stryjewski, Martin E., Arnold Lentnek, William O’Riordan, John Pullman, Paul Anantharajah Tambyah, Jose M. Miró, Vance G. Fowler, Steven L. Barriere, Michael M. Kitt, and G Ralph Corey. “A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study..” Bmc Infect Dis 14 (May 23, 2014). https://doi.org/10.1186/1471-2334-14-289.

PMID
24884578
Full Text

Barriere, Steven L., Martin E. Stryjewski, G Ralph Corey, Fredric C. Genter, and Ethan Rubinstein. “Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies..” Bmc Infect Dis 14 (April 4, 2014). https://doi.org/10.1186/1471-2334-14-183.

PMID
24708675
Full Text

Pages